Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) Director Sells 1,750 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Judy D. Olian sold 1,750 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $412.48, for a total value of $721,840.00. Following the completion of the transaction, the director now owns 5,655 shares of the company’s stock, valued at $2,332,574.40. The trade was a 23.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $386.27 on Friday. The company’s 50 day simple moving average is $362.57 and its 200 day simple moving average is $326.65. The stock has a market capitalization of $17.25 billion, a price-to-earnings ratio of 16.96, a price-to-earnings-growth ratio of 1.17 and a beta of 0.56. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same period last year, the firm posted $5.38 earnings per share. As a group, analysts anticipate that United Therapeutics Co. will post 25.1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on UTHR shares. Bank of America decreased their price objective on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a report on Thursday, August 1st. Jefferies Financial Group lifted their price target on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. The Goldman Sachs Group lifted their price target on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a report on Friday, November 1st. TD Cowen lifted their price target on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, LADENBURG THALM/SH SH lifted their price target on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $370.86.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in UTHR. Meiji Yasuda Asset Management Co Ltd. grew its stake in shares of United Therapeutics by 1.6% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock worth $652,000 after buying an additional 33 shares during the last quarter. Toronto Dominion Bank grew its stake in shares of United Therapeutics by 0.8% during the second quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock worth $1,441,000 after buying an additional 37 shares during the last quarter. ClariVest Asset Management LLC grew its stake in shares of United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after buying an additional 42 shares during the last quarter. Benjamin F. Edwards & Company Inc. grew its stake in shares of United Therapeutics by 14.0% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock worth $109,000 after buying an additional 42 shares during the last quarter. Finally, First Citizens Bank & Trust Co. grew its stake in shares of United Therapeutics by 1.8% during the third quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company’s stock worth $961,000 after buying an additional 48 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.